14:00 - 16:00

TEMPORARY SUPPORT PERFECTIONING COURSE: TEMPORARY LVAD, RVAD, BIVAD, ECMO, ECPELLA

Invalides

A. EL BANAYOSY, Oklahoma City - US, A. COMBES, Paris - FR

• How to minimize Leg ischemia in peripheral ECMO practically

S. HOSSEINI, Tehran - IR
• A long way to go…

G. LEBRETON, Paris - FR
• Percutaneous RVAD associated with HMIII

F. KHALIEL, Riyad - SA
• Options for VA ECMO patients: durable MCS-Transplant and beyond

A. EL BENAYOSY, Oklahoma city - US

14:00 - 15:00

VAD EARLY AND LATE COMPLICATION: HOW TO MANAGE?

Louvre Palais Royal

J.D. SCHMITTO, Hanover - DE, U. JORDE, New York - US

• Outflow graft thrombosis

M. MORSHUIS, Bad Oeynheusen - DE
• Tricuspid valve management

G. WIESELTHALER, San Francisco - US
• Aortic valve regurgitation

C. BERMUDEZ, Philadelphia - US

14:00 - 15:00

R&D: FROM IDEA TO CONCEPTION, ENGINEERING AND FINANCIAL ISSUES

Amphitheatre

D. ZIMPFER, Graz - AT

• P. LEPRINCE, Paris - FR
• S. SCHUELER, Newcastle - GB
• L. FRESIELLO, Enschede - NL
• J. LONG, Oklahoma - US
• D. LOISANCE, Creteil - FR
• S. PIAT, Vélizy-Villacoublay - FR

15:00 - 16:00

CHALLENGING ISSUES REGARDING TRAINING ON ACUTE AND CHRONIC HEART FAILURE ACROSS THE WORLD

Amphitheatre

S.TSUI, Cambridge - GB, N.AISSAOUI, Paris - FR

• J. RIEBANDT, Vienna - AT
• C. DELMAS, Toulouse - FR
• G. DOGAN, Hanover - DE
• N. URIEL, New York - US
• E. RAME, Pennsylvania, US
• G. SAIYDOUN, Paris - FR
• P. LEPRINCE, Paris - FR

14:00 - 16:00

VAD COORDINATOR MEETING - EUMS/ICCAC session

Concorde

A.WOODS, Newcastle - GB, K.HOMANN, Hanover - DE

• You have the power! How VAD Coordinators help shape MCS

J. HAJJ, Charleston - US
• The new kids on the block: Use of ARBNI and SLGT2 inhibitors in MCS therapy

E. RAME, Pennsylvania - US
• Mum, Dad; Are we there yet? Single centre experience of paediatric LVAD implants

C. MCGRAITH, newcastle upon Tyne - GB
• Me, myself and VAD: Patients are the untapped knowledge source

S. KORE, Manchester - GB
• Short or long run: The use of short-term MCS versus durable MCS, are times changing!

K. VANDERMISSEN, Leuven - BE
• You look different to me: The role of the VAD coordinator from a surgeons perspective

J. HANKE, Hanover - DE
• Discussion and Q&A with speakers

16:30 - 18:30

RAPID-FIRE ABSTRACTS SESSION

Amphitheatre

D. ZIMPFER, Graz - AT, J. D. SCHMITTO, Hanover - DE, S. TSUI, Cambridge - GB

• Comparative impact of Impella, central VA ECMO and ECPELLA on myocardial oxygen consumption

K. YASTREBOV, Sydney - AU
• Mutlicenter development and validation of a machine learning model to predict myocardial recovery during LVAD support: the UCAR Score

S. DRAKOS, Salt Lake City - US
• Left ventricle assist device positioning: a comprehensive evaluation

I. HARTYANSZKY, Budapest - HU
• Outcomes and complications after LVAD implantation

G. WASILEWSKI, Krakow - PL
• VA-ECMO for hemodynamic support in massive and sub-massive pulmonary embolism-the path forward

P. BARRETT, Atlanta - US
• Prolonged oxygenator usage for VV ECMO for COVID ARDS: a clinical experience

M. OZGUR, Istanbul - TR
• Conundrum after peripheral VA-ECMO and pulmonary embolectomy: a switch in time saves nine

S. AZIZ, Washington - US
• Heart support pump - RAP-P, Rotary Assisted Pulsatile -Pump

F-H. HORN, Tating - DE
• Long-term outcomes following explantation of durable left ventricular assist device

A.-M. .JAKSTAITE, Hanover - DE
• Change in wound care management reduces cannula site infection rate in patients with paracorporeal VAD

E. WOODS, London - UK
• Phosphodiesterase type 5 inhibitor use is associated with reduced all-cause mortality and ischemic stroke at 24 months postimplant in contemporary centrifugal flow left venticular assist devices

J. KARIMOV, Cleveland - US

09:10 - 11:00

SESSION 1 – ADVANCED HEART FAILURE MANAGEMENT: EDGE OF TOMORROW

Amphitheatre

P. LEPRINCE Paris - FRA, G. LAUFFER,Vienna - AT A. RUHPARWAR, Hanover - DE

• Best Abstract: Mutlicenter development and validation of a machine learning risk model to predict right venticular failure following mechanical circulatory support: the STOP-RVF score

S. DRAKOS, Salt Lake City - US
• Debate: New drugs improve short-term outcome but delay patient referral for advanced heart failure treatment (MCS, transplantation). AGREE

R. KORMOS, Austin - US
• Debate: New drugs improve short-term outcome but delay patient referral for advanced heart failure treatment (MCS, transplantation). DISAGREE

J. BAUERSACHS, Hanover – DE
• Heart failure cardiogenic shock

D. BARAN, Florida – US
• Early recognition of changes in PAP by CardioMEMS helps in early identification of patients that need LVAD therapy and post implant follow up

N. URIEL, New York - US
• Levosimendan as a bridge to surgery in severe chronic heart failure

A. SHIRYAEV, Moscow – RU

11:30 - 13:00

MEET THE EXPERTS

Amphitheatre

J.D. SCHMITTO, Hanover - DE, A. Combes, Paris - FR

• Escalating and de-escalating

A. EL BANAYOSY, Oklahoma City - US
• MCS post transplant

G. LEBRETON, Paris - FR
• LVAD and small ventricle

M. MORSHUIS, Bad Oeynhausen - DE

14:00 - 16:00

SESSION 3 – ELECTROPHYSIOLOGY, CRT AND MCS: COLLABORATIVE WORK?

Amphitheatre

J. BAUERSACHS, Hanover - DE, U.JORDE, New York - US

• Debate: all CRT non-responders should be addressed for LVAD evaluation. Pro

N. URIEL, New York - US
• Debate: all CRT non-responders should be addressed for LVAD evaluation. Con

E. SIMSEK, Izmir - TR
• Temporary support and malignant arrhythmias

M. PINETON DE CHAMBRUN, Paris - FR
• Ventricular rhythm disturbance issues in MCS patients

U. JORDE, New York - US
• How to manage AF in heart failure and LVAD patients

M. LA MEIR, Brussel - BE

16:30 - 18:00

SESSION 4 – PEDIATRIC AND GROWN-UP CONGENITAL HEART DISEASE AND MCS

Amphitheatre

D. ZIMPFER, Graz - AT, G.WIESELTHALER, SAN FRANCISCO-US E.GOLUKHOVA, Moscow - RU

• Best Abstract: Outcome after ECMO therapy in Norwood patients before the bidirectional Glenn operation

F. SEEBER, Linz - AT
• The use of magnetically levitated continuous flow LVAD in paediatrics: “Russian experience”

E. GOLUKHONA, Moscow - RU
• HMIII in smaller patients

U. KERVAN, Ankara - TR
• MCS in GUCH patients: technical issues

D. ZIMPFER, Graz - AT
• TAH in GUCH patients

F. ARABIA, Phoenix - US

18:00 - 19:00

REGISTRIES REPORT

Amphitheatre

B. MEYNS, Leuven - BE, J.HANKE, Hanover - DE G.LEBRETON,Paris - FR

• Euromacs

P. MOHASCI, Zurich - CH
• Francemacs

M. KINDO, Strasbourg - FR
• Imacs

E. RAME, Pennsylvania - US

08:30 - 10:30

SESSION 5 – CARDIOGENIC SHOCK AND SHORT TERM SUPPORT

Amphitheatre

A. EL BANAYOSY, Oklahoma City - US, D.BARAN, Florida - US

• VA ECMO and Impella trials in CS: update

A. COMBES, Paris - FR
• Mid-term survival after VA ECMO weaning: unjustified high rate of death?

P. LEPRINCE, Paris - FR
• Left venticle reverse modeling with Impella 5.5: an animal study

B. MEYNS, Leuven - BE
• Debate: What is the best option in stable patients on VA ECMO with poor potential for recovery. Cardiac transplantation

E. EPAILLY, Strasbourg - FR
• Debate: What is the best option in stable patients on VA ECMO with poor potential for recovery. Long-term MCS (LVAD, BIVAD, TAH)

A. RUHPARWAR, Hanover - DE
• Debate : Frome ECMO to LVAD.Direct LVAD implantation is the best option

D. SAEED, Krefeld - DE
• Debate : From ECMO to LVAD. Intermediary support with Impella is the best option

Y. BARAC, Tel Aviv - IL

11:00 - 13:00

SESSION 6 – DEEP INSIDE DURABLE MCS

Amphitheatre

J.D. SCHMITTO, Hanover - DE, J.LONG, Oklahoma - US S. SCHUELER, Newcastle - GB

• Best Abstract: Pump-LV interaction during long-term support with the HeartMate 3 LVAD

F. CONSOLO, Milano - IT
• Keynote lecture. AI driven revolution: impact on Mechanical Circulatory Support world

A. KILIC, South Carolina - US
• ISHLT guidelines 2023: what’s new

D. SAEED, Krefeld - DE
• From momentum 3 trial: center based criteria for improving outcome?

N. URIEL, New York - US
• Myocardial recovery: what have we learned and future directions

S. DRAKOS, Salt Lake City, US
• Medicolegal issues

M. SLEPIAN, Turcson- US
• What future for durable LAVD and how to energise the field? Technical, market, cardiologist, surgeon and financial issues: difference among continents

14:00 - 16:00

SESSION 7 - GAPS AND OPPORTUNITIES

Room Concorde

D. ZIMPFER, Graz - AT, M. SLEPIAN, Tucson - US B. MEYNS, LEUVEN - BE

• Best Abstract: Outcome of CentriMag™ extracorporeal mechanical circulatory support use in critical cardiogenic shock (INTERMACS 1) patients: Manchester experience

M. JAIN, Manchester - US
• Unleash the potential: Novel HeartMate 3 pump monitoring for improved patient care

T. SCHOGLOFER, Vienna - AT
• In silico and in vitro simulation to support monitoring and controls development for MCSs

L. FRESIELLO, Enschede - NL
• Why LVAD still looks like LVAD and what will lead to change?

S. SCHUELER, Newscastle - GB
• How far miniaturization of VADs is possible?

T. SNYDER, Clichy - FR
• Could a TAH definitely challenge current LVAD?

J. LONG, Oklahoma City - US

16:30 - 18:30

SESSION 8 – INNOVATION

Amphitheatre

M. STRUEBER, Memphis - US, P. LEPRINCE, Paris - FR

• Best Abstract: Advantages of 3D modeling in left ventricular assist device implantation for complex anatomical cases

I.-R. BARABAS, Budapest - HU
• Speed up your patient's blood management with autologous platelets: same™ by i-SEP the new IOCS game changer

A. MANSOUR, Rennes - FR
• Cleveland Clinic continuous flow TAH

J.H. KARIMOV, Cleveland - US
• The Broader Scope of Innovation

R. MOCK, ABBOTT, Plano - US
• The AdjuCor reBEAT-Device: Translational steps of a non-blood-contacting MCS towards the first-in-Human experience

B. SCHMACK, Hanover - DE
• Berlin Heals C-MIC Cardiac Microcurrent Therapy for Chronic Heart Failure - status update

E. RAME, Pennsylvania - US
• A Physiologic Heart Replacement Therapy for advanced heart failure patients

P. JANSEN, CARMAT, Velizy - FR
• CorWave: A synchronized pulsatile LVAD with autonomous control features – A progress update

T. SNYDER, Clichy – FR
• FineHeart FlowMaker: a small, fully implantable, intra-cardiac pump, demonstrates the ability to induce durable recovery in HF

L. BARANDON, Bordeaux – FR
• Corheart 6 : small and innovative VAD technology for the future of HF therapy
• Realheart TAH - a preclinical update of the world's first 4-chamber artificial heart

I.L. PERKINS, Vasteras - SE
• Design and preliminary use of a new Ventricular Assist Device

N. DONG, Wuhan - CN

08:00 - 08:45

SESSION 9 – SELECTED CASES

Amphitheatre

G. LEBRETON,Paris - FR, M. STRUEBER, Memphis - US

• Decision tree in biventricular failure: escalation and de-escalation

G. DOGAN, Hanover - DE,
• Mechanical circulatory support with Impella in septic shock

Z. HAIDARI, Essen - DE
• LVAD in ischemic cardiomyopathy: an unexpected recovery

G. KHUBULAVA, Saint-Petersburg - RU

08:45 -10:05

SESSION 10 – MECHANICAL DEVICES IN LUNG SUPPORT

Amphitheatre

Y. BARAC, Tel Aviv - IL, E. EPAILLY, Strasbourg - FR

• Artificial lung: animal studies

M. ANRAKU,Tokyo - JP
• MCS and pulmonary embolism

O. SANCHEZ, Paris - FR
• MCS and pulmonary hypertension

O. MERCIER, Le Plessis-Robinson - FR
• MCS and lung transplantation

M. STRUEBER, Memphis - US
• Panel Discussion with all the speakers

10:30 - 11:50

SESSION 11 – ADVANCED HEART FAILURE THERAPIES: ALTERNATIVE TREATMENTS?

Amphitheatre

D. ZIMPFER, Graz - AT, J.D. SCHMITTO, Hanover - DE, A. EL BANAYOSY, Oklahoma City - US

• Heart failure in Women

M. AL QASEER, Dammam - SA
• Stem cell therapy: any hope in advanced heart failure management?

P. MENASCHE, Paris - FR
• Xenotransplantation: how the first in-man implantation will impact the field?

M. MOHIUDDIN, Baltimore - US